接受用过链激酶治疗的供体所提供肾脏的受者会产生抗链激酶抗体吗？
Do recipients of kidneys from donors treated with streptokinase develop anti-streptokinase antibodies?
作者信息
Mi H, Gupta A, Gok M A, Asher J, Shenton B K, Stamp S, Carter V, Del Rio Martin J, Soomro N A, Jaques B C, Manas D M, Talbot D
机构信息
Department of Renal and Liver Transplant, The Freeman Hospital, High Heaton, Newcastle Upon Tyne NE7 7DN, United Kingdom.
出版信息
Transplant Proc. 2005 Oct;37(8):3272-3. doi: 10.1016/j.transproceed.2005.09.035.
Streptokinase is used for preflush for non-heart-beating donors (NHBDs) in our center. The aim of this study was to evaluate whether the use of thrombolytic streptokinase results in the production of anti-streptokinase antibodies in the recipients after renal transplantation. Recipient sera taken prior to and at 1 and 6 months posttransplant were tested for the presence of antibodies to streptokinase using an enzyme-linked immunosorbent assay assay. No differences were detected between a group of 18 recipients who had kidneys from thrombolytic-treated NHBDs and a further group of 18 who received NHBD kidneys without such treatment.
在我们中心，链激酶用于非心脏骤停供体（NHBDs）的预冲洗。本研究的目的是评估使用溶栓剂链激酶是否会导致肾移植受者产生抗链激酶抗体。使用酶联免疫吸附测定法检测移植前以及移植后1个月和6个月时采集的受者血清中抗链激酶抗体的存在情况。在一组接受经溶栓治疗的NHBDs肾脏的18名受者与另一组接受未经此类治疗的NHBDs肾脏的18名受者之间未检测到差异。
Zotero 插件